Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel group study to explore the efficacy of PTR-36 in adult patients with bronchial asthma (Phase 2)

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled, parallel group study to explore the efficacy of PTR-36 in adult patients with bronchial asthma (Phase 2)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 001 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Teijin Pharma

    • Most Recent Events

    • 16 Mar 2020 Results, assessing time to asthma worsening in the overall population and post-hoc subgroups, published on the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 07 Nov 2019 Results published in an American College of Allergy, Asthma & Immunology (ACAAI) 2019 Annual Scientific Meeting.
    • 25 Jul 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top